Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease

O Hansson, S Lehmann, M Otto, H Zetterberg… - Alzheimer's research & …, 2019 - Springer
The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ 42), total
Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau 181) have proven diagnostic …

Current state of Alzheimer's fluid biomarkers

JL Molinuevo, S Ayton, R Batrla, MM Bednar… - Acta …, 2018 - Springer
Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the …

P Lewczuk, P Riederer, SE O'bryant… - The world journal of …, 2018 - Taylor & Francis
In the 12 years since the publication of the first Consensus Paper of the WFSBP on
biomarkers of neurodegenerative dementias, enormous advancement has taken place in …

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease

MJ Leitão, A Silva-Spínola, I Santana, V Olmedo… - Alzheimer's Research & …, 2019 - Springer
Background Ongoing efforts within the Alzheimer's disease (AD) field have focused on
improving the intra-and inter-laboratory variability for cerebrospinal fluid (CSF) biomarkers …

The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: a review

O Hansson, A Mikulskis, AM Fagan, C Teunissen… - Alzheimer's & …, 2018 - Elsevier
Introduction Cerebrospinal fluid (CSF) biomarkers have the potential to improve the
diagnostic accuracy of Alzheimer's disease, yet there is a lack of harmonized preanalytical …

Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive …

I Baldeiras, I Santana, MJ Leitão, H Gens… - Alzheimer's research & …, 2018 - Springer
Background Cerebrospinal fluid (CSF) biomarkers have been used to increase the evidence
of underlying Alzheimer's disease (AD) pathology in mild cognitive impairment (MCI) …

Derivation of cutoffs for the Elecsys® amyloid β (1–42) assay in Alzheimer's disease

LM Shaw, T Waligorska, L Fields… - Alzheimer's & …, 2018 - Wiley Online Library
Abstract Introduction An Elecsys® Amyloid β (Aβ [1–42]) immunoassay cutoff for
classification of patients with Alzheimer's disease was investigated. Methods Cerebrospinal …

Proteomic approaches for the discovery of biofluid biomarkers of neurodegenerative dementias

BC Carlyle, BA Trombetta, SE Arnold - Proteomes, 2018 - mdpi.com
Neurodegenerative dementias are highly complex disorders driven by vicious cycles of
intersecting pathophysiologies. While most can be definitively diagnosed by the presence of …

Bridging the gap between fluid biomarkers for Alzheimer's disease, model systems, and patients

C Bjorkli, A Sandvig, I Sandvig - Frontiers in aging neuroscience, 2020 - frontiersin.org
Alzheimer's disease (AD) is a debilitating neurodegenerative disease characterized by the
accumulation of two proteins in fibrillar form: amyloid-β (Aβ) and tau. Despite decades of …

How to handle adsorption of cerebrospinal fluid amyloid β (1–42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ42 …

E Willemse, K van Uffelen, B Brix, S Engelborghs… - Alzheimer's & …, 2017 - Elsevier
Introduction We aimed to investigate factors defining amyloid β (1–42)(Aβ 1–42) adsorption
during preanalytical workup of cerebrospinal fluid (CSF). Methods CSF was transferred to …